Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022 Featured Updates to the NCCN Guidelines

被引：53

作者：

Wierda, William G. ^{[1
]}

Brown, Jennifer ^{[2
]}

Abramson, Jeremy S. ^{[3
]}

Awan, Farrukh ^{[4
]}

Bilgrami, Syed F. ^{[5
]}

Bociek, Greg ^{[6
]}

Brander, Danielle ^{[7
]}

Chanan-Khan, Asher A. ^{[8
]}

Coutre, Steve E. ^{[9
]}

Davis, Randall S. ^{[10
]}

Eradat, Herbert ^{[11
]}

Fletcher, Christopher D. ^{[12
]}

Gaballa, Sameh ^{[13
]}

Ghobadi, Armin ^{[14
,15
]}

Hamid, Muhammad Saad ^{[16
]}

Hernandez-Ilizaliturri, Francisco ^{[17
]}

Hill, Brian ^{[18
,19
]}

Kaesberg, Paul ^{[20
]}

Kamdar, Manali ^{[21
]}

Kaplan, Lawrence D. ^{[22
]}

Khan, Nadia ^{[23
]}

Kipps, Thomas J. ^{[24
]}

Ma, Shuo ^{[25
]}

Mato, Anthony ^{[26
]}

Mosse, Claudio ^{[27
]}

Schuster, Stephen ^{[28
]}

Siddiqi, Tanya ^{[29
]}

Stephens, Deborah M. ^{[30
]}

Ujjani, Chaitra ^{[31
]}

Wagner-Johnston, Nina ^{[32
]}

Woyach, Jennifer A. ^{[33
]}

Ye, J. Christine ^{[34
]}

Dwyer, Mary A. ^{[35
]}

Sundar, Hema ^{[35
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA

[3] Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA

[4] UT Southwestern Simmons Comprehens Canc Ctr, Dallas, TX USA

[5] Smilow Canc Hosp, Yale Canc Ctr, New Haven, CT USA

[6] Fred & Pamela Buffett Canc Ctr, Omaha, NE USA

[7] Duke Canc Inst, Durham, NC USA

[8] Mayo Clin, Canc Ctr, Rochester, MN USA

[9] Stanford Canc Inst, Stanford, CA USA

[10] ONeal Comprehens Canc Ctr UAB, Birmingham, AL USA

[11] UCLA, Jonsson Comprehens Canc Ctr, Los Angeles, CA USA

[12] Univ Wisconsin, Carbone Canc Ctr, Madison, WI 53706 USA

[13] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[14] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO 63110 USA

[15] Washington Univ, Sch Med, St Louis, MO USA

[16] Univ Tennessee, Hlth Sci Ctr, St Jude Chidrens Res Hosp, Knoxville, TN 37996 USA

[17] Roswel Pk Comprehens Canc Ctr, Buffalo, NY USA

[18] Univ Hosp Seidman Canc Ctr, Case Comprehensve Canc Ctr, Cleveland, OH USA

[19] Cleveland Clin, Tausslg Canc Inst, Cleveland, OH 44106 USA

[20] UC Davis Comprehens Canc Ctr, Davis, CA USA

[21] Univ Colorado, Canc Ctr, Boulder, CO 80309 USA

[22] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[23] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[24] UC San Diego Moores Canc Ctr, San Diego, CA USA

[25] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA

[26] Mem Sloan Kettering Canc Ctr, Ithaca, NY USA

[27] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[28] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[29] City Hope Natl Med Ctr, Duarte, CA USA

[30] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA

[31] Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, 1124 Columbia St, Seattle, WA 98104 USA

[32] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA

[33] Ohio State Univ, Comprehenslve Canc Ctr, James Canc Hosp & Solove Res Inst, Columbus, OH 43210 USA

[34] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI 48109 USA

[35] Natl Comprehens Canc Network, Philadelphia, PA USA

来源：

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2022年 / 20卷 / 06期

关键词：

MINIMAL RESIDUAL DISEASE; CHLORAMBUCIL PLUS OBINUTUZUMAB; FLOW-CYTOMETRY; OPEN-LABEL; 1ST-LINE TREATMENT; FOLLOW-UP; PHASE-II; IBRUTINIB; VENETOCLAX; CLL;

D O I：

10.6004/jnccn.2022.0031

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The treatment landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has significantly evolved in recent years. Targeted therapy with Bruton???s tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors has emerged as an effective chemotherapy-free option for patients with previously untreated or relapsed/refractory CLL/SLL. Undetectable minimal residual disease after the end of treatment is emerging as an important predictor of progression-free and overall survival for patients treated with fixed-duration BCL-2 inhibitor-based treatment. These NCCN Guidelines Insights discuss the updates to the NCCN Guidelines for CLL/ SLL specific to the use of chemotherapy-free treatment options for patients with treatment-na??ve and relapsed/refractory disease.

引用

页码：622 / 634

页数：13

共 50 条

[41] Management of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in the Era of Targeted Therapies
Rainone, Michael
Siddiqi, Tanya
CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2022, 17 (01) : 39 - 45
[42] B-Cell Lymphomas, Version 3.2019 Featured Updates to the NCCN Guidelines
Zelenetz, Andrew D.
Gordon, Leo I.
Abramson, Jeremy S.
Advani, Ranjana H.
Bartlett, Nancy L.
Caimi, Paolo F.
Chang, Julie E.
Chavez, Julio C.
Christian, Beth
Fayad, Luis E.
Glenn, Martha J.
Habermann, Thomas M.
Harris, Nancy Lee
Hernandez-Ilizaliturri, Francisco
Kaminski, Mark S.
Kelsey, Christopher R.
Khan, Nadia
Krivacic, Susan
LaCasce, Ann S.
Mehta, Amitkumar
Nademanee, Auayporn
Rabinovitch, Rachel
Reddy, Nishitha
Reid, Erin
Roberts, Kenneth B.
Smith, Stephen D.
Snyder, Erin D.
Swinnen, Lode J.
Vose, Julie M.
Dwyer, Mary A.
Sundar, Hema
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (06): : 651 - 661
[43] Frontline Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Targeted Therapy vs. Chemoimmunotherapy
Small, Sara
Ma, Shuo
CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2021, 16 (04) : 325 - 335
[44] Colorectal Cancer Screening, Version 1.2024: Featured Updates to the NCCN Guidelines
Ness, Reid M.
Llor, Xavier
Abbass, Mohammad Ali
Bishu, Shrinivas
Chen, Christopher T.
Cooper, Gregory
Early, Dayna S.
Friedman, Mark
Fudman, David
Giardiello, Francis M.
Glaser, Kathryn
Gurudu, Surya
Hall, Michael
Huang, Lyen C.
Issaka, Rachel
Katona, Bryson
Kidambi, Trilokesh
Lazenby, Audrey J.
Maratt, Jennifer
Markowitz, Arnold J.
Marsano, Joseph
May, Folasade P.
Mayer, Robert J.
Olortegui, Kinga
Patel, Swati
Peter, Shajan
Porter, Laura D.
Shafi, Mehnaz
Stanich, Peter P.
Terdiman, Jonathan
Vu, Peter
Weiss, Jennifer M.
Wood, Elizabeth
Cassara, Carly J.
Sambandam, Vaishnavi
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2024, 22 (07): : 438 - 446
[45] Gastrointestinal Stromal Tumors Version 2.2022 Featured Updates to the NCCN Guidelines
von Mehren, Margaret
Kane, John M.
Riedel, Richard F.
Sicklick, Jason K.
Pollack, Seth M.
Agulnik, Mark
Bui, Marilyn M.
Carr-Ascher, Janai
Choy, Edwin
Connelly, Mary
Dry, Sarah
Ganjoo, Kristen N.
Gonzalez, Ricardo J.
Holder, Ashley
Homsi, Jade
Keedy, Vicki
Kelly, Ciara M.
Kim, Edward
Liebner, David
McCarter, Martin
McGarry, Sean, V
Mesko, Nathan W.
Meyer, Christian
Pappo, Alberto S.
Parkes, Amanda M.
Petersen, Ivy A.
Poppe, Matthew
Schuetze, Scott
Shabason, Jacob
Spraker, Matthew B.
Zimel, Melissa
Bergman, Mary Anne
Sundar, Hema
Hang, Lisa E.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2022, 20 (11): : 1204 - 1214
[46] Underrepresentation of Small Lymphocytic Lymphoma in Clinical Trials for Chronic Lymphocytic Leukemia
Puckrin, Robert
Owen, Carolyn
Peters, Anthea
EUROPEAN JOURNAL OF HAEMATOLOGY, 2025, 114 (04) : 636 - 640
[47] Biliary Tract Cancers, Version 2.2023 Featured Updates to the NCCN Guidelines
Benson, Al B., III
D'Angelica, Michael I.
Abrams, Thomas
Abbott, Daniel E.
Ahmed, Aijaz
Anaya, Daniel A.
Anders, Robert
Are, Chandrakanth
Bachini, Melinda
Binder, David
Borad, Mitesh
Bowlus, Christopher
Brown, Daniel
Burgoyne, Adam
Castellanos, Jason
Chahal, Prabhleen
Cloyd, Jordan
Covey, Anne M.
Glazer, Evan S.
Hawkins, William G.
Iyer, Renuka
Jacob, Rojymon
Jennings, Lawrence
Kelley, R. Kate
Kim, Robin
Levine, Matthew
Palta, Manisha
Park, James O.
Raman, Steven
Reddy, Sanjay
Ronnekleiv-Kelly, Sean
Sahai, Vaibhav
Singh, Gagandeep
Stein, Stacey
Turk, Anita
Vauthey, Jean-Nicolas
Venook, Alan P.
Yopp, Adam
McMillian, Nicole
Schonfeld, Ryan
Hochstetler, Cindy
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2023, 21 (07): : 695 - 704
[48] Non-Small Cell Lung Cancer, Version 6.2015 Featured Updates to the NCCN Guidelines
Ettinger, David S.
Wood, Douglas E.
Akerley, Wallace
Bazhenova, Lyudmila A.
Borghaei, Hossein
Camidge, David Ross
Cheney, Richard T.
Chirieac, Lucian R.
D'Amico, Thomas A.
Demmy, Todd L.
Dilling, Thomas J.
Dobelbower, M. Chris
Govindan, Ramaswamy
Grannis, Frederic W., Jr.
Horn, Leora
Jahan, Thierry M.
Komaki, Ritsuko
Krug, Lee M.
Lackner, Rudy P.
Lanuti, Michael
Lilenbaum, Rogerio
Lin, Jules
Loo, Billy W., Jr.
Martins, Renato
Otterson, Gregory A.
Patel, Jyoti D.
Pisters, Katherine M.
Reckamp, Karen
Riely, Gregory J.
Rohren, Eric
Schild, Steven E.
Shapiro, Theresa A.
Swanson, Scott J.
Tauer, Kurt
Yang, Stephen C.
Gregory, Kristina
Hughes, Miranda
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2015, 13 (05): : 515 - 524
[49] Use of BTK Inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Practical Guidance
St-Pierre, Frederique
Ma, Shuo
BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY, 2022, 12 : 81 - 98
[50] Non-Small Cell Lung Cancer, Version 1.2020 Featured Updates to the NCCN Guidelines
Ettinger, David S.
Wood, Douglas E.
Aggarwal, Charu
Aisner, Dara L.
Akerley, Wallace
Bauman, Jessica R.
Bharat, Ankit
Bruno, Debora S.
Chang, Joe Y.
Chirieac, Lucian R.
D'Amico, Thomas A.
Dilling, Thomas J.
Dobelbower, Michael
Gettinger, Scott
Govindan, Ramaswamy
Gubens, Matthew A.
Hennon, Mark
Horn, Leora
Lackner, Rudy P.
Lanuti, Michael
Leal, Ticiana A.
Lin, Jules
Loo, Billy W., Jr.
Martins, Renato G.
Otterson, Gregory A.
Patel, Sandip P.
Reckamp, Karen L.
Riely, Gregory J.
Schild, Steven E.
Shapiro, Theresa A.
Stevenson, James
Swanson, Scott J.
Tauer, Kurt W.
Yang, Stephen C.
Gregory, Kristina
Hughes, Miranda
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (12): : 1464 - 1472

← 1 2 3 4 5 →